Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

Strategies for preventing calcium oxalate stones

Vadim A. Finkielstein and David S. Goldfarb
CMAJ May 09, 2006 174 (10) 1407-1409; DOI: https://doi.org/10.1503/cmaj.051517
Vadim A. Finkielstein
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David S. Goldfarb
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

About 10% of people will experience nephrolithiasis in their lifetime, and about 70% of those will have recurrences. About 80% of stones are calcium based, and about 80% of those are calcium oxalate stones. We discuss here briefly the evidence for the prevention of calcium oxalate stones through dietary and pharmacologic measures.

Urinary risk factors

Both genetic and environmental factors contribute to stone formation, but the genes responsible for the heritable aspect of stone formation have not been delineated definitively. Mainstays of calcium stone prevention involve manipulation of urine chemistries (urine sodium, citrate, oxalate, uric acid and calcium levels as well as urine specific gravity). The urinary risk factors most often implicated in stone formation are listed in Table 1. Hypercalciuria is the most common trait associated with calcium stones, yet its cause in most patients remains unclear. It is still often referred to as “idiopathic hypercalciuria.” The efficacy of classifying hypercalciuria on the basis of cause remains controversial and of unproven value in clinical management.

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 1.

Dietary modification

Fluid intake

The cornerstone of management is to increase urine volume. The effect appears to be linear, with a point of diminishing return reached at urine volumes of more than 2.5 L per day. We prescribe an intake of 2.5–3 L of fluids per day.

There are data to suggest that the type of fluid ingested matters. Epidemiologic studies show that drinking coffee and beer decreases the risk of stones. Drinking grapefruit juice consistently increases stone risk for unclear reasons, whereas lemon juice, higher in citrate content, might have beneficial effects on urinary chemistry but its ingestion has not been shown to prevent stones.

Calcium

Studies of dietary calcium's effect on stone recurrence rates have led to major changes in nonpharmacologic manipulation. Epidemiologic evidence shows an inverse relation between dietary calcium intake and recurrence rates. This is probably best explained by calcium's inhibition of intestinal oxalate absorption. A randomized controlled trial (RCT) assigned men with hypercalciuria to follow either a diet low in calcium (400 mg) and oxalate or a diet higher in calcium (1200 mg) with restricted intake of oxalate, protein and salt.1 At 5 years, the latter group had a 51% lower rate of stone recurrence than those following a low-calcium diet. Although controversy persists and replication of these findings under other clinical circumstances would be desirable, low-calcium diets are not recommended and can exacerbate the well-documented association of hypercalciuria with low bone mineral density and increased fracture rates.2 Whether calcium supplements could have a similar effect in lowering stone recurrence rates has not been tested. Taking calcium carbonate supplements with meals reduces oxaluria, whereas taking them at bedtime increases calciuria and has no effect on oxaluria.3 The preferred calcium supplement for people at risk of stone formation is calcium citrate because it helps to increase urinary citrate excretion. We recommend a dose of 200–400 mg if dietary calcium cannot be increased.

Oxalate

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Box 1.

The intake of foods high in oxalate should be limited. Although there are many such foods, some more frequently than others have been shown to be most at fault for raising urine oxalate levels (Box 1). Their impact might be mitigated by accompanying them with additional fluids and dietary sources of calcium to diminish oxalate absorption. No pharmacologic intervention has definitively been shown to be effective. Of note, since vitamin C can convert to oxalate, the use of vitamin C supplements may increase oxaluria and be associated with an increased risk of stone formation; therefore, the dose of these supplements should be limited to less than 1000 mg/d.

Sodium

Calcium excretion is directly linked to sodium excretion. Reductions in dietary sodium reduce calciuria, but no RCT of sodium restriction alone has been performed. The successful diet mentioned earlier that was higher in calcium and restricted intake of oxalate, protein and salt1 achieved a reduction in calcium excretion despite the higher calcium intake. This effect was attributed to the reduction in dietary sodium intake to less than 2 g/d.

Protein

The ingestion of animal protein has adverse affects on urine chemistries: it lowers citrate excretion and increases calcium and uric acid excretion. Epidemiologic data show that it correlates well with the prevalence of stone formation. The recent popularity of diets low in carbohydrates and high in animal protein have refocused attention on protein intake as a risk factor for stones.4 Patients with recurrent stones should minimize their protein intake to less than 80 g/d.

Role of diabetes and obesity in stone formation

Recent data have suggested an increased prevalence of stones among people with diabetes and among obese people. Insulin resistance may reduce urinary citrate excretion and increase calcium excretion, and a greater body mass index is associated with increases in urinary oxalate excretion. Low urine pH is associated with increased risk of uric acid stones as well. Weight loss (through a mechanism other than a diet high in animal protein) and improved diabetes control may help to prevent stone formation in appropriate patients, although this approach has yet to be tested in an RCT.

Drug therapy

Thiazide diuretics

Thiazide diuretics (e.g., hydrochlorothiazide, chlorthalidone and indapamide) have been proven in RCTs to be effective in reducing calciuria and stone recurrence. These drugs also induce positive calcium balance and thereby increase bone mineral density. Sodium restriction must be employed, and hypokalemia must be avoided since it can lead to hypocitraturia. The usual starting dose is 12.5–25 mg of chlorthalidone or hydrochlorothiazide. Most patients should receive supplementation with potassium citrate. Amiloride may help avoid hypokalemia, but triamterene should be avoided because of its low solubility.

Alkalinizing agents

Citrate inhibits the formation and growth of calcium crystals. Its use has been advocated both in patients with low urinary citrate excretion and in patients who have had calcium oxalate stones but who do not have this urinary abnormality. Use of the potassium salt is preferred, since sodium citrate supplementation will lead to increased calciuria.

Allopurinol

A minority of patients with calcium oxalate stones have hyperuricosuria as their only identifiable metabolic risk factor. Uric acid facilitates the precipitation of calcium oxalate crystals. A single RCT demonstrated the efficacy of allopurinol, 100 mg 3 times daily (although we prescribe 300 mg once daily), to reduce calcium stone formation.5 No benefit of allopurinol in patients with hypercalciuria was identified.

Fish oil

Interest in fish oil supplementation arose from the observation that kidney stones were virtually absent in the Inuits of Greenland, a population with a dietary mainstay of fresh fish. Supplementation with eicosapentaenoic acid leads to reduced calciuria but has not been tested in an RCT.

Summary

A limited number of RCTs have shown that a good strategy for preventing the recurrence of calcium oxalate stones includes increasing fluid intake, increasing the dietary intake of calcium and restricting the intake of salt, animal protein and oxalate-rich foods. Treatment with a thiazide diuretic, allopurinol and citrate has a role in selected cases. Several other means of manipulating urinary chemistries have not been adequately tested in RCTs directed at stone prevention.

Footnotes

  • This article has been peer reviewed.

    Competing interests: None declared.

REFERENCES

  1. 1.↵
    Borghi L, Schianchi T, Mecschi T, et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 2002;346:77-84.
    OpenUrlCrossRefPubMed
  2. 2.↵
    Lauderdale DS, Thisted RA, Wen M, et al. Bone mineral density and fracture among prevalent kidney stone cases in the Third National Health and Nutrition Examination Survey. J Bone Miner Res 2001;16:1893-8.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Domrongkitchaiporn S, Sopassathit W, Stitchantrakul W, et al. Schedule of taking calcium supplement and the risk of nephrolithiasis. Kidney Int 2004;65:1835-41.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Reddy ST, Wang CY, Sakhaee K, et al. Effect of low-carbohydrate high-protein diets on acid–base balance, stone-forming propensity, and calcium metabolism. Am J Kidney Dis 2002;40:265-74.
    OpenUrlCrossRefPubMed
  5. 5.↵
    Ettinger B, Tang A, Citron JT, et al. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med 1986;315:1386-9.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 174 (10)
CMAJ
Vol. 174, Issue 10
9 May 2006
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Strategies for preventing calcium oxalate stones
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Strategies for preventing calcium oxalate stones
Vadim A. Finkielstein, David S. Goldfarb
CMAJ May 2006, 174 (10) 1407-1409; DOI: 10.1503/cmaj.051517

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Strategies for preventing calcium oxalate stones
Vadim A. Finkielstein, David S. Goldfarb
CMAJ May 2006, 174 (10) 1407-1409; DOI: 10.1503/cmaj.051517
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Urinary risk factors
    • Dietary modification
    • Drug therapy
    • Summary
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • Highlights of this issue
  • Dans ce numéro
  • PubMed
  • Google Scholar

Cited By...

  • Drosophila melanogaster as a function-based high-throughput screening model for antinephrolithiasis agents in kidney stone patients
  • Google Scholar

More in this TOC Section

  • Penicillin allergy delabelling of patients at risk of sexually transmitted infections in primary care
  • Phthiriasis palpebrarum
  • Penicillin allergy delabelling in pregnancy
Show more Practice

Similar Articles

Collections

  • Topics
    • Urology

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire